Maternal hypoxia
Education on Maternal hypoxia and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with claims from the patent-pending application clearly labeled as hypothesis.
Research status: Investigational / hypothesis
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent-pending application US20220160847A1 (Appl. No. 17/527,730) and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Maternal hypoxia and Alpha-1 Antitrypsin is described in Mark Egly's patent-pending application. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Maternal hypoxia?
Maternal hypoxia is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Maternal conditions affect pregnancy and maternal health.
What Mark Egly's patent-pending application discusses
Hypoxia refers to insufficient oxygenation and is a prominent feature of inflammation associated with numerous disease states. Hypoxia is common in inflamed and infected tissues, which are characterized by oxygen and nutrient deprivation. Sadiku and Walmsley provide a review of literature on innate immunometabolism and discuss the role of hypoxia in innate cell metabolic reprogramming and how this determines immune responses. Specifically, hypoxia prolongs neutrophil survival. Maternal hypoxia can lead to fetal low brain oxygenation. A fetus can suffer severe problems from maternal hypoxia, including cerebral palsy, periventricular leukomalacia, and brain damage. As described by Golan et al, magnesium sulfate has been used to reduce hypoxia-induced motor disabilities in offspring. As shown by Coleman and Rund, asthma and epilepsy are non-obstetric conditions that may result in maternal hypoxia. Administration of AAT can prevent or control maternal hypoxia during pregnancy by preventing non-obstetric conditions that lead to hypoxia. Due to the link between AATD and maternal hypoxia, in one embodiment AAT may be used to treat, control, or prevent maternal hypoxia in patients, either…
How this may relate to Alpha-1
Mark Egly's patent-pending application proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Maternal hypoxia, Mark Egly's patent-pending application suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Maternal hypoxia, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support:
Sources and references
References checked July 26, 2026
- Alpha-1 antitrypsin deficiency (MedlinePlus Genetics (NIH))Research status: Established clinical knowledge
- American Thoracic Society / European Respiratory Society statements on lung disease (locate current AATD guidance) (American Thoracic Society)Research status: Established clinical knowledgeUse the current ATS/ERS AATD statements applicable to your practice.
- Method of Preventing and/or Treating a Plurality of Diseases — patent pending: published U.S. application US20220160847A1 (Appl. No. 17/527,730) (Google Patents)Research status: Investigational / hypothesis
Educational content only. Not a diagnosis or treatment plan. Work with your clinician for personal medical decisions.